17 October 2024, 13:00 - 13:45 PM CET (*)
Free Educational Webinar
With RWE expert Prof. Dr. Thomas Wilke
National HTA bodies require comparative evidence, i.e. evidence of the effectiveness and safety of your asset against the Standard of Care in different regions. This will be even more so after implementation of the new European HTA (Joint Clinical Assessment: JCA). In addition, payors generally ignore any evidence that does not come from comparative studies.
If RCT evidence is not available, comparative RWE evidence is one option to close existing evidence gaps.
Register for our upcoming educational webinar and learn from our RWE expert Thomas Wilke:
What is better and what is more accepted: comparative RWE versus indirect comparisons based on trials.
Synthetic control groups and post-approval comparative RWE studies: How do they work?
Existing guidance and guidelines for comparative RWE studies
About Prof. Dr. Thomas Wilke:
Expert faculty member of the popular 1-day Generating RWE for Optimising Market/Patient Access course.
25+ years of experience in leading and conducting European and German RWE studies, including database studies, linked data studies, medical chart reviews and surveys.
In addition to being an academic researcher and author of numerous articles, Thomas is leading the University-affiliated institute IPAM and acts as senior scientist at GIPAM, a consultancy specialised on European RWE studies.
Please note that this webinar is only open to managers working in pharma/biotech/medtech companies. For your registration to be approved, please enter your COMPANY EMAIL address.
(*) If you cannot attend the webinar, please note that a recorded playback will be sent to all registrants after the webinar.
Learn more from this expert at the following short duration course(s):
Generating RWE for Optimising Market/Patient Access
With Prof. Dr. Thomas Wilke
